0000000000936549

AUTHOR

C. Buckley

showing 2 related works from this author

Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Resear…

2021

Abstract Background Epidemiological studies in atrial fibrillation (AF) illustrate that clinical complexity increase the risk of major adverse outcomes. We aimed to describe European AF patients’ clinical phenotypes and analyse the differential clinical course. Methods We performed a hierarchical cluster analysis based on Ward’s Method and Squared Euclidean Distance using 22 clinical binary variables, identifying the optimal number of clusters. We investigated differences in clinical management, use of healthcare resources and outcomes in a cohort of European AF patients from a Europe-wide observational registry. Results A total of 9363 were available for this analysis. We identified three …

RegistrieResearch Reportmedicine.medical_specialtyMajor adverse outcomeCardiovascular risk factorsCluster analysisRisk FactorsInternal medicineClinical phenotypeAtrial FibrillationEpidemiologyHumansMedicineRegistriesCluster analysiAtrial fibrillation; Clinical management; Clinical phenotypes; Cluster analysis; Major adverse outcomes; Humans; Phenotype; Registries; Research Report; Risk Factors; Atrial FibrillationClinical managementbusiness.industryProportional hazards modelRisk FactorHazard ratioRAtrial fibrillationClinical phenotypesMajor adverse outcomesGeneral Medicinemedicine.diseaseAtrial fibrillationConfidence intervalPhenotypeCohortMedicineObservational studybusinessResearch ArticleHumanBMC Medicine
researchProduct

Minimal manifestation status and prednisone withdrawal in the MGTX trial

2020

ObjectiveTo examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG).MethodsThis study is a post hoc analysis of data from a randomized trial of thymectomy in MG (Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy [MGTX]). MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody–positive MG without thymoma. Patients were randomized 1:1 to thymectomy plus prednisone vs prednisone alone. Participants were age 18–65 years at enr…

Malemedicine.medical_treatmentAzathioprinelaw.invention0302 clinical medicineRandomized controlled trialPrednisonelawMedicineSingle-Blind Method030212 general & internal medicineYoung adultMiddle AgedThymectomyCombined Modality TherapySubstance Withdrawal Syndrome3. Good healthSettore MED/26 - NEUROLOGIA6.1 PharmaceuticalsAnesthesiaadolescent; adult; animals; combined modality therapy; female; humans; immunosuppressive agents; male; middle aged; myasthenia gravis; prednisone; rats; single-blind method; substance withdrawal syndrome; thymoma; thymus neoplasms; young adult; thymectomyCognitive SciencesFemaleImmunosuppressive Agentsmedicine.drugAdultThymomaAdolescentThymomaClinical Trials and Supportive ActivitiesClinical SciencesMGTX study groupAutoimmune DiseaseArticleYoung Adult03 medical and health sciencesRare DiseasesClinical ResearchMyasthenia GravisPost-hoc analysisAnimalsHumansNeurology & Neurosurgerybusiness.industryNeurosciencesEvaluation of treatments and therapeutic interventionsThymus Neoplasmsmedicine.diseaseMyasthenia gravisRatsThymectomyPrednisoneNeurology (clinical)business030217 neurology & neurosurgeryNeurology
researchProduct